{
    "root": "3620b4be-63bc-dd15-e063-6394a90ac3b4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valproic Acid",
    "value": "20250527",
    "ingredients": [
        {
            "name": "CORN OIL",
            "code": "8470G57WFM"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "VALPROIC ACID",
            "code": "614OI1Z5WI"
        }
    ],
    "indications": "valproic acid capsules indicated : monotherapy adjunctive therapy complex partial seizures ; sole adjunctive therapy simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
    "contraindications": "valproic acid capsules intended oral . ( 2.1 ) simple complex absence seizures : start 10 15 mg/kg/day , increasing 1-week intervals 5 10 mg/kg/week seizure control limiting side effects ( 2.1 ) safety doses 60 mg/kg/day established ( 2.1 , 2.2 )",
    "warningsAndPrecautions": "white , oblong soft-gelatin capsule imprinted pa2120 , contains 250 mg valproic acid ndc : 70518-0079-00 ndc : 70518-0079-01 ndc : 70518-0079-02 packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch softgels protected moisture humidity stored 59 77°f ( 15 25°c ) per container label . dispense tight , light-resistant container defined usp/nf . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "valproic acid capsules administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . valproic acid contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase γ ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . valproic acid contraindicated patients known hypersensitivity [ ( 5.12 ) ] . valproic acid contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : valproic acid contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications_original": "Valproic Acid Capsules are intended for oral administration. ( 2.1 ) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1-week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects ( 2.1 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 )",
    "warningsAndPrecautions_original": "Each white, oblong soft-gelatin capsule is imprinted PA2120, contains 250 mg valproic acid\n                  \n                  NDC: 70518-0079-00\n                  NDC: 70518-0079-01\n                  NDC: 70518-0079-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  The softgels should be protected from moisture and humidity and stored between 59 to 77°F (15 to 25°C) as per the container label. Dispense in a tight, light-resistant container as defined in the USP/NF.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Valproic Acid Capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients with known hypersensitivity to the drug\n  \n   [see Warnings and Precautions (\n   \n    5.12)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients with known urea cycle disorders\n  \n   [see Warnings and Precautions (\n   \n    5.6)]\n  \n   .\n \n  \n                     For use in prophylaxis of migraine headaches: Valproic Acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception \n  \n   [see Warnings and Precautions (\n   \n    5.2,\n                           5.3,\n   \n    5.4\n                        \n                        ) and Use in Specific Populations (\n                        \n                           8.1\n                        \n                        )]."
}